Find a Clinical Trial

Trial Description: This research is being done to compare rates of hair loss of people with metastatic breast who use scalp cooling versus those who do not use scalp cooling after receiving standard of care treatment with either sacituzumab govitecan, trastuzumab deruxtecan, or eribulin. The name of the study intervention involved in this study is: - Paxman Scalp Cooling System

• Conditions: chemotherapy-induced alopecia, metastatic breast cancer
• Phase: II
• Trial ID: NCT04986579
• Protocol ID: 21-169

Trial Description: This study will examine the safety and tolerability of ladiratuzumab vedotin (LV) in patients with metastatic breast cancer. LV will be given alone or in combination with trastuzumab.

• Conditions: her2 mutations breast neoplasms, her2 positive breast neoplasms, hormone receptor positive breast neoplasms, triple negative breast neoplasms
• Phase: I
• Trial ID: NCT01969643
• Protocol ID: 14-306

Trial Description: A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 in patients with metastatic castration resistant prostate cancer, metastatic breast cancer, non-small cell lung cancer or advanced solid tumours.

• Conditions: advanced solid tumors, metastatic breast cancer, metastatic castration-resistant prostate cancer, non-small cell lung cancer
• Phase: I/II
• Trial ID: NCT03568656
• Protocol ID: 21-430

Trial Description: This study will evaluate the efficacy and safety of inavolisib in combination with Phesgo (pertuzumab, trastuzumab, and rHuPH20 injection for subcutaneous use) compared with placebo in combination with Phesgo, as maintenance therapy, after induction therapy in participants with previously untreated HER2-positive advanced breast cancer (ABC).

• Conditions: metastatic breast cancer
• Phase: III
• Trial ID: NCT05894239
• Protocol ID: 23-279

Trial Description: This research study is studying three combinations of drugs as treatments for breast cancer. The drugs involved in this study are: - Fulvestrant - Fulvestrant with Palbociclib - Fulvestrant with Palbociclib and Avelumab

• Conditions: metastatic breast cancer
• Phase: II
• Trial ID: NCT03147287
• Protocol ID: 17-101

Trial Description: This is an open-label, three-part, multiple-dose study to evaluate safety, tolerability, and efficacy of U3-1402 in patients with HER3-positive metastatic breast cancer. HER3 is a unique member of the human epidermal growth factor receptor, which defines a certain type of cancer. The number of patients and treatment cycles are not fixed in this study. Subjects who continue to derive clinical benefit from the study treatment in the absence of withdrawal of consent, progressive disease (PD), unacceptable toxicity, or death may continue the study treatment until the end of the trial.

• Conditions: metastatic breast cancer
• Phase: I/II
• Trial ID: NCT02980341
• Protocol ID: 18-382

Trial Description: The primary objective of this study is to assess and compare the efficacy and safety of sacituzumab govitecan-hzi versus treatment of physician's choice (TPC) in participants with hormonal receptor-positive (HR+) human epidermal growth factor receptor 2 (HER2-) negative metastatic breast cancer (MBC).

• Conditions: metastatic breast cancer
• Phase: III
• Trial ID: NCT03901339
• Protocol ID: 19-225

Trial Description: The reason for this study is to determine the recommended phase 2 dose of the study drug LY3295668 erbumine in participants with breast cancer that has spread to other parts of the body.

• Conditions: metastatic breast cancer
• Phase: I
• Trial ID: NCT03955939
• Protocol ID: 19-314

Trial Description: To demonstrate the efficacy of enobosarmin the treatment of androgen receptor positive (AR+) and estrogen receptor positive (ER+) metastatic breast cancer (MBC) as measured by radiographic progression free survival (rPFS).

• Conditions: metastatic breast cancer
• Phase: III
• Trial ID: NCT04869943
• Protocol ID: 22-305

Trial Description: The purpose of this Phase II study is to evaluate the efficacy and safety of Continuous Low- Irradiance Photodynamic Therapy (CLIPT) when used with Verteporfin in the treatment of cutaneous metastases of breast cancer for which no curative or significantly palliative therapy exists, including chest wall therapy.

• Conditions: metastatic breast cancer
• Phase: II
• Trial ID: NCT02939274
• Protocol ID: 16-370

Trial Description: The reason for this study is to see if the study drug LY3484356 alone or in combination with other anticancer therapies is safe and effective in participants with advanced or metastatic breast cancer or endometrial cancer.

• Conditions: advanced breast cancer, breast cancer, endometrial cancer, metastatic breast cancer
• Phase: I
• Trial ID: NCT04188548
• Protocol ID: 20-118

Trial Description: This research study is studying a combination of drugs as a possible treatment for metastatic breast cancer. The interventions involved in this study are: - Pembrolizumab - Trastuzumab emtansine (also called T-DM1)

• Conditions: breast cancer
• Phase: I
• Trial ID: NCT03032107
• Protocol ID: 16-492

Trial Description: This study evaluates the safety of abemaciclib in combination therapies (letrozole, anastrozole, tamoxifen, exemestane, exemestane plus everolimus, trastuzumab, LY3023414 plus fulvestrant, pertuzumab plus trastuzumab with loperamide, or ongoing endocrine therapy) for breast cancer that has spread to other parts of the body.

• Conditions: breast neoplasms
• Phase: I
• Trial ID: NCT02057133
• Protocol ID: 14-070

Trial Description: This research study is studying a drug called Abemaciclib as a possible treatment for have metastatic triple-negative type of breast cancer.

• Conditions: breast cancer
• Phase: II
• Trial ID: NCT03130439
• Protocol ID: 17-024

Trial Description: This phase II trial studies how well FDG-PET/CT works in assessing the response of patients with breast cancer that has spread to the bones or mostly to the bones (bone-dominant metastatic breast cancer). Diagnostic procedures, such as FDG-PET/CT, may work better in measuring breast cancer activity before and after treatment compared to other standard imaging tests.

• Conditions: anatomic stage iv breast cancer ajcc v8, hormone receptor positive breast carcinoma, metastatic breast carcinoma, prognostic stage iv breast cancer ajcc v8
• Phase: II
• Trial ID: NCT04316117
• Protocol ID: 20-430

Trial Description: A phase 2 non-randomized study to assess the safety and efficacy of the combination of tucatinib and trastuzumab with capecitabine for the treatment of leptomeningeal metastases in HER2-neu positive breast cancer.

• Conditions: leptomeningeal disease, metastatic breast cancer
• Phase: II
• Trial ID: NCT03501979
• Protocol ID: 19-387

Trial Description: This research is evaluating the impact of a 12-week prolonged nightly fasting (POF) and exercise intervention on metabolic markers and patient reported outcomes in women with metastatic breast cancer (MBC) initiating endocrine therapy in combination with palbociclib or alpelisib.

• Conditions: breast cancer, metastatic breast cancer
• Phase: Feasibility / Pilot
• Trial ID: NCT04708860
• Protocol ID: 20-503

Trial Description: This study will evaluate the efficacy, safety and tolerability of trastuzumab deruxtecan compared with investigator's choice chemotherapy in human epidermal growth factor receptor (HER)2-low, hormone receptor (HR) positive breast cancer patients whose disease has progressed on endocrine therapy in the metastatic setting.

• Conditions: advanced or metastatic breast cancer
• Phase: III
• Trial ID: NCT04494425
• Protocol ID: 20-536

Trial Description: CONTESSA TRIO is a multi-cohort, multicenter, Phase 2 study of tesetaxel, an investigational, orally administered taxane, in patients with metastatic breast cancer (MBC). In Cohort 1, approximately 200 patients with triple-negative MBC who have not received prior chemotherapy for advanced disease will be randomized 1:1:1 to receive tesetaxel plus either: (1) nivolumab; (2) pembrolizumab; or (3) atezolizumab. The primary efficacy endpoints for Cohort 1 are objective response rate (ORR) and progression free survival (PFS) in patients with programmed death-ligand 1 (PD-L1

• Conditions: breast cancer
• Phase: II
• Trial ID: NCT03952325
• Protocol ID: 19-170

Trial Description: Part 1: to assess the safety and tolerability of pyrotinib and to define the maximum tolerated dose (MTD) of pyrotinib in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive advanced solid tumors (metastatic breast cancer, gastric cancer, or other solid tumors that have no targeted agent as standard of care). Part 2: to estimate the overall response rate (ORR) for patients with HER2-positive metastatic breast cancer (mBC) and HER2 mutant non-small cell lung cancer (NSCLC) treated at the RP2D (or MTD).

• Conditions: breast cancer, gastric cancer, nsclc, solid tumors
• Phase: I
• Trial ID: NCT02500199
• Protocol ID: 16-265

Trial Description: This research study is studying a drug called atezolizumab as a possible treatment HER2-positive metastatic breast cancer (MBC) that has spread to the brain. The names of the study drugs involved in this study are: - Atezolizumab - Pertuzumab - Trastuzumab

• Conditions: central nervous system metastases, her2-positive metastatic breast cancer
• Phase: II
• Trial ID: NCT03417544
• Protocol ID: 17-546

Trial Description: This research is being done to evaluate the safety and effectiveness of Onvansertib in combination with Paclitaxel in triple-negative breast cancer (TNBC) that has spread to other parts of the body. The names of the study interventions involved in this study are: - Onvansertib - Paclitaxel

• Conditions: breast cancer, her2-negative breast cancer, hormone receptor negative breast carcinoma, hormone receptor/growth factor receptor-negative breast cancer, inflammatory breast cancer, invasive breast cancer, locally advanced breast cancer, metastatic breast cancer, triple negative breast cancer (tnbc), unresectable breast carcinoma
• Phase: I/II
• Trial ID: NCT05383196
• Protocol ID: 22-008

Trial Description: This research study is studying a drug called Neratinib with and without Fulvestrant as possible treatments for HER2-positive breast cancer . The interventions involved in this study are: - Neratinib and Fulvestrant - Neratinib alone

• Conditions: breast cancer
• Phase: II
• Trial ID: NCT03289039
• Protocol ID: 17-318

Trial Description: The open-label Phase Ib portion of this study will evaluate the safety and pharmacokinetics of ipatasertib in combination with palbociclib and fulvestrant to identify a dose of ipatasertib that can be combined with palbociclib and fulvestrant in the Phase III portion. The randomized Phase III portion of this study will evaluate the efficacy, safety, and patient-reported outcome (PRO) objectives of ipatasertib + palbociclib + fulvestrant compared with placebo + palbociclib + fulvestrant in patients with HR+ HER2-, locally advanced unresectable or metastatic breast cancer who had relapsed during adjuvant endocrine therapy or progressed during the initial 12 months of first-line endocrine therapy in locally advanced unresectable or metastatic breast cancer.

• Conditions: breast cancer
• Phase: III
• Trial ID: NCT04060862
• Protocol ID: 19-602

Trial Description: This is a multicenter, Phase 1b/2 trial. The phase 1b part of the trial aims to determine the RP2D of elacestrant when administered in combination with alpelisib, everolimus, palbociclib, and ribociclib. The Phase 2 part of the trial will evaluate the efficacy and safety of the various combinations in patients with ER+/HER2- advanced/metastatic breast cancer.

• Conditions: breast cancer, metastatic breast cancer
• Phase: I/II
• Trial ID: NCT05563220
• Protocol ID: 23-216

Trial Description: This study is being done to see if anti-HER2 treatment be safely stopped in patients with HER2-positive metastatic breast cancer (MBC) that have had exceptional response to treatment. Exceptional response" is considered as cancer progression being controlled for three years or more since starting anti-HER2 treatment.

• Conditions: breast cancer, her2-positive breast cancer, metastatic breast cancer
• Phase: II
• Trial ID: NCT05721248
• Protocol ID: 22-655

Trial Description: A Phase 2, clinical study in advanced, metastatic breast cancer that will evaluate CX-2009 monotherapy in both Hormone Receptor(HR) positive/HER2 negative breast cancer and in TNBC, and evaluate CX-2009+CX-072 in TNBC

• Conditions: breast cancer, breast neoplasms, breast neoplasms hormone receptor positive/her2 negative, breast neoplasms triple-negative, neoplasms
• Phase: II
• Trial ID: NCT04596150
• Protocol ID: 21-130

Trial Description: The primary objective of this study is to demonstrate that the combination of palbociclib with anti-HER2 therapy plus endocrine therapy is superior to anti-HER2-based therapy plus endocrine therapy alone in improving the outcomes of subjects with hormone receptor-positive, HER2+ metastatic breast cancer.

• Conditions: estrogen receptor positive breast cancer, her-2 positive breast cancer
• Phase: III
• Trial ID: NCT02947685
• Protocol ID: 17-220

Trial Description: This research study is a way of gaining new knowledge about the combination of Taselisib with other drugs in the treatment of metastatic breast cancer. Taselisib is an investigational drug which works by blocking a protein called PI3K (phosphoinositide 3-kinase) that helps cancer cells grow. This drug has been used in laboratory experiments and information from these studies suggests that this drug may help to prevent or slow the growth of cancer cells. The main purpose of this study is to find the appropriate dose of Taselisib to be used with other drugs in further clinical studies. This is an open-label, 3+3 dose-escalation phase Ib study to identify the Maximum Tolerated Dose(s) (MTD) and to identify the recommended phase 2 dose (RP2D) of Taselisib. This study will be conducted in 4 separate arms. (A-D).

• Conditions: metastatic breast cancer, recurrent breast cancer
• Phase: I
• Trial ID: NCT02390427
• Protocol ID: 15-024

Trial Description: The purpose of the trial is to evaluate a patient's response to a Fibroblast Growth Factor Receptor (FGFR) inhibitor, futibatinib (TAS-120), used either alone or in combination with the hormonal therapy, fulvestrant. This study will be conducted in patients with metastatic breast cancer who have specific Fibroblast Growth Factor Receptor gene abnormalities and who have previously received conventional therapies to treat their breast cancer, or who are not able to tolerate certain cancer therapies. This study will also evaluate the safety of taking futibatinib, or futibatinib and fulvestrant, by learning about the potential side effects.

• Conditions: fgfr 1 high amplification, fgfr2 amplification, metastatic breast cancer
• Phase: II
• Trial ID: NCT04024436
• Protocol ID: 19-844

Trial Description: This research study is studying immunotherapy as a possible treatment for metastatic Triple Negative Breast Cancer (TNBC) in participants who are HLA-A2+. The drugs involved in this study are: - PVX-410 - Pembrolizumab - Hiltonol - Montanide

• Conditions: metastatic breast cancer, triple negative breast cancer
• Phase: I
• Trial ID: NCT03362060
• Protocol ID: 17-328

Trial Description: This research study is for patients with metastatic breast cancer. - Metastatic means that the cancer has spread beyond the breast. In addition, through genetic testing of the blood or tumor, an altered gene has been found that suggests the tumor may not be able to repair its genetic material (DNA) when it becomes damaged. - This aspect of the cancer may cause it to be more sensitive - that is, more effectively killed by certain types of drugs such as the study agent being evaluated in this trial, Olaparib. - Olaparib is a type of drug known as a PARP inhibitor. Some types

• Conditions: atm gene mutation, brip1 gene mutation, chek2 gene mutation, invasive breast cancer, metastatic breast cancer, nbn gene mutation, palb2 gene mutation, rad51 gene mutation, somatic mutation breast cancer (brca1), somatic mutation breast cancer (brca2)
• Phase: II
• Trial ID: NCT03344965
• Protocol ID: 17-428

Trial Description: This research study is studying a combination of targeted therapy and hormonal therapy as a possible treatment for breast cancer that has spread to other places in the body and is hormone receptor positive (HR+) and HER2-negative. The names of the study interventions involved in this study are: - Palbociclib - Everolimus - Exemestane

• Conditions: hormone receptor (hr)-positive breast cancer, human epidermal growth factor 2 negative carcinoma of breast
• Phase: I/II
• Trial ID: NCT02871791
• Protocol ID: 16-177

Trial Description: This is an open-label, randomized, active comparator, multicenter, international Phase 3 study of NKTR-102 versus TPC in patients with metastatic breast cancer who have stable brain metastases and have been previously treated with an anthracycline, a taxane, and capecitabine in either the adjuvant or metastatic setting (prior anthracycline may be omitted if medically appropriate or contraindicated for the patient).

• Conditions: breast cancer, metastasis
• Phase: III
• Trial ID: NCT02915744
• Protocol ID: 16-553

Trial Description: This research study is evaluating the safety and effectiveness of Sacituzumab Govitecan with or without Pembrolizumab in metastatic HR+/HER2- breast cancer. The names of the study interventions involved in this study are: - Sacituzumab govitecan (IMMU-132) - Pembrolizumab (Keytruda®; MK-3475)

• Conditions: her2-negative breast cancer, hr-positive breast cancer, invasive breast cancer, metastatic breast cancer
• Phase: II
• Trial ID: NCT04448886
• Protocol ID: 20-153

Trial Description: This research study is studying the usefulness of magnetic resonance imaging (MRI) to screen for brain metastases (spread of the breast cancer to the brain).

• Conditions: breast cancer, her2-positive breast cancer, hormone receptor positive malignant neoplasm of breast, inflammatory breast cancer, metastatic breast cancer, triple negative breast cancer
• Phase: II
• Trial ID: NCT04030507
• Protocol ID: 19-066

Trial Description: CONTESSA 2 is a multinational, multicenter, Phase 2 study of tesetaxel in patients with HER2 negative, HR positive, locally advanced or metastatic breast cancer (LA/MBC) not previously treated with a taxane. The primary objective of the study is to establish the efficacy of tesetaxel plus a reduced dose of capecitabine based on objective response rate (ORR) as assessed by an Independent Radiologic Review Committee (IRC). 152 patients were enrolled.

• Conditions: breast cancer
• Phase: II
• Trial ID: NCT03858972
• Protocol ID: 19-221

Trial Description: The study is intended to show superiority of AZD9833 in combination with CDK4/6 inhibitor (palbociclib, abemaciclib or ribociclib) versus aromatase inhibitors (anastrozole or letrozole) in combination with CDK4/6 inhibitor in patients with hormone receptor-positive (HR-positive), human epidermal growth factor receptor 2-negative (HER2-negative) metastatic breast cancer with detectable ESR1 mutation.

• Conditions: er-positive her2-negative breast cancer
• Phase: III
• Trial ID: NCT04964934
• Protocol ID: 21-518

Trial Description: This phase II trial studies the side effects and how well palbociclib and letrozole or fulvestrant works in treating patients aged 70 years and older with estrogen receptor positive, HER2 negative breast cancer that has spread to other places in the body. Palbociclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as letrozole or fulvestrant, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving palbociclib and letrozole or fulvestrant may work better in treating patients with breast cancer. The trial will explore factors other than chronologic age that can affect toxicity rates as identified using a cancer-specific geriatric assessment.

• Conditions: estrogen receptor-positive breast cancer, her2/neu negative, stage iv breast cancer ajcc v6 and v7
• Phase: II
• Trial ID: NCT03633331
• Protocol ID: 18-739

Trial Description: The study will evaluate the efficacy and safety of trastuzumab deruxtecan (also known as T-DXd, DS-8201a), either alone or in combination with pertuzumab, in treating patients with Human epidermal growth factor receptor 2 (HER2)-positive breast cancer as a first line of treatment in the metastatic setting.

• Conditions: breast cancer; her2-positive; metastatic
• Phase: III
• Trial ID: NCT04784715
• Protocol ID: 21-480

Trial Description: This is a Phase 1/2 dose escalation and cohort expansion study and will assess the safety, tolerability and anti-tumor activity of ARV-471 alone and in combination with palbociclib (IBRANCE®) in patients with estrogen receptor positive/human epidermal growth factor receptor 2 negative (ER+/HER2-) locally advanced or metastatic breast cancer, who have received prior hormonal therapy and chemotherapy in the locally advanced/metastatic setting.

• Conditions: breast cancer
• Phase: I/II
• Trial ID: NCT04072952
• Protocol ID: 20-449

Trial Description: The main purpose of this study is to compare progression-free survival for women with hormone receptor positive (HR+), human epidermal growth factor receptor (HER2) negative advanced breast cancer receiving either abemaciclib + fulvestrant or fulvestrant alone. Participants will be randomized to abemaciclib or placebo in a 2:1 ratio. The study will last about 9 months for each participant. For the endocrine naïve cohort, all participants will received abemaciclib + fulvestrant.

• Conditions: breast neoplasms
• Phase: III
• Trial ID: NCT02107703
• Protocol ID: 14-518

Trial Description: This Phase III, randomized, open-label, multicenter study will evaluate the efficacy and safety of giredestrant plus everolimus compared with the physician's choice of endocrine therapy plus everolimus in participants with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer who have had previous treatment with cyclin-dependent kinase 4/6 inhibitors (CDK4/6is) and endocrine therapy, either in the locally advanced/metastatic or the adjuvant setting.

• Conditions: estrogen receptor (er)-positive her2-negative locally advanced or metastatic breast cancer
• Phase: III
• Trial ID: NCT05306340
• Protocol ID: 22-265

Trial Description: At the time of study termination, NUV-422-02 was a first-in-human, open-label, Phase 1 dose escalation study designed to evaluate the safety and efficacy of NUV-422. The study population comprised adults with recurrent or refractory high-grade gliomas (HGGs), metastatic breast cancer (mBC), with and without brain metastases, and recurrent or refractory metastatic castration-resistant prostate cancer (mCRPC). All patients self-administered NUV-422 orally in 28-day cycles until disease progression, toxicity, withdrawal of consent, or termination of the study.

• Conditions: advanced breast cancer, advanced breast carcinoma, breast cancer, breast carcinoma, breast tumor, cancer of breast, cancer of prostate, cancer of the breast, cancer of the prostate, castrate resistant prostate cancer, castration resistant prostatic neoplasms, castration-resistant prostate cancer, glial cell tumors, glioblastoma, glioma, glioma malignant, glioma mixed, malignant tumor of breast, metastatic breast cancer, metastatic breast carcinoma, prostate cancer, prostate neoplasm, prostatic cancer, recurrent glioblastoma
• Phase: I/II
• Trial ID: NCT04541225
• Protocol ID: 20-517

Trial Description: This research study is studying a combination of drugs as a possible treatment for breast cancer. The drugs involved in this study are: - Group A: Trastuzumab (Herceptin) + Vinorelbine (Navelbine) - Group B: Trastuzumab + Vinorelbine + Avelumab - Group C: Trastuzumab + Vinorelbine + Avelumab + Utomilumab (PF-05082566)

• Conditions: breast cancer
• Phase: II
• Trial ID: NCT03414658
• Protocol ID: 17-455

Trial Description: CONTESSA is a multinational, multicenter, randomized, Phase 3 study of tesetaxel in patients with HER2 negative, HR positive LA/MBC previously treated with a taxane in the neoadjuvant or adjuvant setting. The primary objective of the study is to compare the efficacy of tesetaxel plus a reduced dose of capecitabine versus the approved dose of capecitabine alone based on progression-free survival (PFS) as assessed by the Independent Radiologic Review Committee (IRC). 685 patients were enrolled

• Conditions: breast cancer
• Phase: III
• Trial ID: NCT03326674
• Protocol ID: 18-547

Trial Description: This study will compare DS-8201a to physician choice standard treatment. Participants must have HER2-low breast cancer that has been treated before. Participants' cancer: - Cannot be removed by an operation - Has spread to other parts of the body

• Conditions: breast cancer
• Phase: III
• Trial ID: NCT03734029
• Protocol ID: 18-663

Trial Description: This phase IIa trial studies the side effects of abemaciclib monotherapy in treating patients age 70 years and older with hormone receptor positive, HER2 negative breast cancer that has spread to other places in the body.

• Conditions: anatomic stage iv breast cancer ajcc v8, hormone receptor positive breast carcinoma, metastatic breast carcinoma, prognostic stage iv breast cancer ajcc v8
• Phase: II
• Trial ID: NCT04305834
• Protocol ID: 21-707

Trial Description: Primary Objective: To determine whether amcenestrant per overall survival (os) improves progression free survival (PFS) when compared with an endocrine monotherapy of the choice of the physician, in participants with metastatic or locally advanced breast cancer Secondary Objectives: - To compare the overall survival in the 2 treatment arms - To assess the objective response rate in the 2 treatment arms - To evaluate the disease control rate in the 2 treatment arms - To evaluate the clinical benefit rate in the 2 treatment arms - To evaluate the duration of response in the 2

• Conditions: breast cancer metastatic
• Phase: II
• Trial ID: NCT04059484
• Protocol ID: 19-391

Trial Description: This is a Phase 1b open-label, 2-part study in 2 treatment groups. The 2 treatment groups are as follows: Treatment Group 1: OP-1250 in combination with ribociclib (KISQALI®, Novartis Pharmaceuticals Corporation). Treatment Group 2: OP-1250 in combination with alpelisib (PIQRAY®, Novartis Pharmaceuticals Corporation

• Conditions: advanced breast cancer, her2-negative breast cancer, hr-positive breast cancer, metastatic breast cancer
• Phase: I
• Trial ID: NCT05508906
• Protocol ID: 23-378